

CLAIMS

What is claimed is:


1. A compound selected from Formula III', Formula IV', and Formula XIV:



(III')



(IV')



(XIV)

or a pharmaceutically acceptable salt thereof;

wherein:




R^{15} is selected from R^{16} and R^{17};



R^{16} is selected from:

(i) $–C(O)C_3$-C_{30}alkylR^5, -$C(O)C_3$-C_{30}alkenylR^5, -$C(O)C_3$-C_{30}alkynylR^5, -$C(O)C_3$-C_{30}alkenylalkynylR^5, $–C(O)C_3$-C_{30}alkyl, -$C(O)C_3$-C_{30}alkenyl, -$C(O)C_3$-C_{30}alkynyl, and -$C(O)C_3$-C_{30}alkenylalkynyl;



(ii) an unsaturated fatty acid residue selected from the carbonyl fragment taken from -$C(O)(CH_2)_7(CH)_2CH_2(CH)_2(CH_2)_4CH_3$), $–C(O)(CH_2)_2(CHCHCH_2)_6CH_3$), $–C(O)(CH_2)_3(CHCHCH_2)_5CH_3$), $–C(O)(CH_2)_7(CHCHCH_2)_3CH_3$), stearidonic acid, y-linolenic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, euric acid, nervonic acid and mead acid; and






(iii) polyethylene glycol, polypropylene glycol, polypropylene oxide, polylactic acid, poly(lactic-co-glycolic acid), polyglycolic acid, a polyester, a polyamide,


, , ,

, and ;

R^{17} is H or -C(O)A;

R^{30} is selected from polyethylene glycol, polypropylene glycol, polypropylene oxide, polylactic acid, poly(lactic-co-glycolic acid), , ,

, , , , and ;

R^{31} is selected from hydrogen, A, -COOH, -C(O)A, alkyl, alkoxy, alkenyl, alkynyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxy, polyethylene glycol, and ;











wherein each R^{30} with a terminal carboxy group is optionally substituted to create an ester;

R^{42} is selected from

(i) -N=CH-C_3-C_{30}alkenylR^5, -N=CH-C_3-C_{30}alkynylR^5, -N=CH-C_3-C_{30}alkenylalkynylR^5, -N=C_1-C_{30}alkylR^5, -N=CH-C_3-C_{30}alkenyl, -N=CH-C_3-C_{30}alkynyl, -N=CH-C_3-C_{30}alkenylalkynyl, -N=C_1-C_{30}alkyl, -NHC_3-C_{30}alkenylR^5, -NH-C_3-C_{30}alkynylR^5, -NH-C_5-C_{30}alkenylalkynylR^5, -NHC_0-C_{30}alkylR^5, -NHC_3-C_{30}alkenylR^{16}, -NH-C_3-C_{30}alkynylR^{16},

-NH-C_5-C_{30}alkenylalkynylR^{16}, and -NHC_0-C_{30}alkylR^{16};

(ii) an imine, amine or amide linked unsaturated fatty acid residue selected from a derivative of linoleic acid, docosahexaenoic acid, eicosapentaenoic acid, alpha-linolenic acid, stearidonic acid, y-linolenic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, euric acid, nervonic acid and mead acid;

(iii) an amine or amide linked polypropylene glycol, an amine or amide linked polypropylene oxide, an amine or amide linked polylactic acid, an amine or amide linked poly(lactic-co-glycolic acid),  ,  ,  ,  ,  ,  ,  ,  ,  ,  , an amine or amide linked polyglycolic acid, a polyester, and a polyamide; and

(iv) -NHC(O)C_{1-20}alkyl, -NHC(O)C_{1-20}alkenyl, -NHC(O)C_{1-20}alkynyl, -NHC(O)(C_{1-20}alkyl with at least one R^5 substituent on the alkyl chain), -NHC(O)(C_{1-20}alkenyl with at least one R^5 substituent on the alkenyl chain) -NHC(O)(C_{1-20}alkynyl with at least one R^5 substituent on the alkynyl chain), -NH(lactic acid)$_{2-20}$C(O)C_{1-20}alkyl,

-NH(lactic acid)$_{2-10}$C(O)C_{1-20}alkyl, -NH(lactic acid)$_{4-20}$C(O)C_{1-20}alkyl,

-NH(lactic acid)$_{2-20}$C(O)C_{1-10}alkyl, -NH(lactic acid)$_{2-20}$C(O)C_{4-10}alkyl, -NH(lactic acid)$_{2-20}$C(O)OH, -NH(lactic acid)$_{2-10}$C(O)OH, -NH(lactic acid)$_{4-20}$C(O)OH,


-NH(lactic acid)$_{2\text{-}10}$C(O)OH, -NH(lactic acid)$_{4\text{-}10}$C(O)OH, -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{1\text{-}20}$alkyl, -NH(lactide-co-glycolide)$_{4\text{-}10}$C(O)C$_{1\text{-}20}$alkyl, -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{4\text{-}20}$alkyl, -NH(glycolic acid)$_{2\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, -NH(glycolic acid)$_{4\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, -NH(lactic acid)$_{4\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, -NH(lactic acid)$_{2\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, NH(lactic acid)$_{2\text{-}10}$C(O)C$_{4\text{-}10}$alkyl, -NH(lactic acid)$_{2\text{-}10}$C(O)C$_{4\text{-}10}$alkyl, and -NH(lactic acid)$_{2\text{-}10}$C(O)C$_{4\text{-}10}$alkyl;

R^5 is selected from halogen, hydroxyl, cyano, mercapto, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxy, -S(O)$_2$alkyl, -S(O)alkyl, -P(O)(Oalkyl)$_2$, B(OH)$_2$, -Si(CH$_3$)$_3$, -COOH, -COOalkyl, and -CONH$_2$;

A is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxy, and alkyloxy; and

x and y are independently selected from an integer between 1 and 10.


2. The compound of claim 1, of formula



,

or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1, of formula:



,


or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, of formula:





,

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 2, wherein R^{30} is selected from 

,




, and 

.


6. The compound of claim 5, wherein R^{30} is 

.

7. The compound of claim 6, wherein x = 1.

8. The compound of claim 5, wherein R^{30} is 


.


9. The compound of claim 5, wherein R^{30} is 

.

10. The compound of any one of claims 1-2, 5, and 8-9,
wherein:
R^{31} is –C(O)A; and
A is aryloxy, alkyoxy, or alkyl.

11. The compound of claim 10, wherein A is methyl.

12. The compound of claim 3 or 4, wherein R^{42} is .

13. The compound of claim 3 or 4, wherein R^{42} is .

14. The compound of claim 3 or 4, wherein R^{42} is selected from -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{1\text{-}20}$alkyl, -NH(lactide-co-glycolide)$_{4\text{-}10}$C(O)C$_{1\text{-}20}$alkyl, -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{1\text{-}10}$alkyl, and -NH(lactide-co-glycolide)$_{2\text{-}10}$C(O)C$_{4\text{-}20}$alkyl.


15. The compound of any one of claims 1, 3-4, and 12-14, wherein R^{15} is R^{17} and R^{17} is hydrogen.

16. The compound of any one of claims 1-15, wherein x is 1, 2, 3, 4, or 5.

17. The compound of any one of claims 1-15, wherein x is 6, 7, 8, 9, or 10.


18. The compound of any one of claims 1-5 and 8-15, wherein x is 1.

19. The compound of claim 2 of the formula




or a pharmaceutically acceptable salt thereof.


20. The compound of claim 2 of the formula




,



,




, or




or a pharmaceutically acceptable salt thereof.

21. The compound of claim 2 of the formula






or a pharmaceutically acceptable salt thereof.

22. The compound of claim 3 of the formula:







or a pharmaceutically acceptable salt thereof.

23. The compound of claim 3 of the formula


,

, or

,


or a pharmaceutically acceptable salt thereof.

24. The compound of claim 4 of the formula


,

,

, or


or a pharmaceutically acceptable salt thereof.





25. A compound selected from Formula XV:




(XV)



or a pharmaceutically acceptable salt thereof;



wherein:

R^{32} is R^{35};

R^{35} is selected from

,

,

,

,


, and 
;

R^{51} is 
, 
,


or 
;


R^{15} is selected from R^{16} and R^{17};

R^{16} is selected from:

(i) $–C(O)C_3$-C_{30}alkylR^5, -$C(O)C_3$-C_{30}alkenylR^5, -$C(O)C_3$-C_{30}alkynylR^5, -$C(O)C_3$-C_{30}alkenylalkynylR^5, $–C(O)C_3$-C_{30}alkyl, -$C(O)C_3$-C_{30}alkenyl, -$C(O)C_3$-C_{30}alkynyl, and -$C(O)C_3$-C_{30}alkenylalkynyl;

(ii) an unsaturated fatty acid residue selected from the carbonyl fragment taken from -$C(O)(CH_2)_7(CH)_2CH_2(CH)_2(CH_2)_4CH_3$), $–C(O)(CH_2)_2(CHCHCH_2)_6CH_3$), $–C(O)(CH_2)_3(CHCHCH_2)_5CH_3$), $–C(O)(CH_2)_7(CHCHCH_2)_3CH_3$), stearidonic acid, y-linolenic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, euric acid, nervonic acid and mead acid; and


(iii) polyethylene glycol, polypropylene glycol, polypropylene oxide, polylactic acid, poly(lactic-co-glycolic acid), polyglycolic acid, a polyester, a polyamide,





R^{17} is selected from H and -C(O)A;


A is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxy, and alkyloxy; and

x and y are independently selected from an integer between 1 and 30.

26. The compound of claim 25, wherein R^{35} is .

27. The compound of claim 25, wherein R^{35} is .

28. The compound of any one of claims 25-27, wherein R^{51} is .

29. The compound of any one of claims 25-27, wherein R^{51} is .

30. The compound of any one of claims 25-29, wherein R^{15} is R^{17} and R^{17} is hydrogen.

31. The compound of any one of claims 25-30, wherein x and y are independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.


32. The compound of claim 31, wherein x and y are independently selected from 1, 2, 3, 4, 5, and 6.

33. The compound of claim 32, wherein x is 1 or 2 and y is selected from 1, 2, 3, and 4.


34. The compound of claim 33, wherein x is 1 and y is 3.

35. The compound of claim 33, wherein x is 1 and y is 4.


36. The compound of claim 25 of the formula




,



,




, or




or a pharmaceutically acceptable salt thereof.

37. The compound of claim 25 of the formula



or



or a pharmaceutically acceptable salt thereof.

38. A pharmaceutical composition comprising a compound of any one of claims 1-37 in a pharmaceutically acceptable carrier.

39. Use of a compound of any one of claims 1-37, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of an ocular disorder to a host in need thereof wherein the disorder is selected from glaucoma, age-related macular degeneration (AMD), a disorder related to an increase in intraocular pressure (IOP), a disorder related to neuroprotection, or diabetic retinopathy.

40. The use of claim 39, wherein the disorder is optic nerve damage caused by high intraocular pressure (IOP).

41. The use of claim 39, wherein the disorder is age-related macular degeneration.

42. The use of claim 39, wherein the disorder is glaucoma.

43. The use of claim 41, wherein the age-related macular degeneration is wet age-related macular degeneration.

44. The use of claim 39, wherein the medicament is to be administered via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, circumcorneal, or tear duct injection.

45. The use of claim 44, wherein the medicament is to be administered via intravitreal injection.

46. The use of any one of claims 39-45, wherein the host is a human.